Jointown Pharmaceutical Group Co., Ltd. Quarterly Results: Standalone & Consolidated Reports

Quarterly Results

Results Snapshot

YoYQoQ

Figures in Million

Consolidate Quarterly Results

Sep'25

Jun'25

Mar'25

Dec'24

Sep'24

Jun'24

Mar'24

Net Sales

38,220.37

39,090.03

42,016.18

38,380.75

36,258.17

36,698.73

40,366.45

Other Operating Income

0.00

Total Operating income

38,220.37

39,090.03

42,016.18

38,380.75

36,258.17

36,698.73

40,366.45

Raw Material Cost

35,092.31

36,199.83

39,099.51

35,732.32

33,494.96

33,657.04

37,708.80

Purchase of Finished goods

0.00

(Increase) / Decrease In Stocks

0.00

Employee Cost

0.00

Power Cost

0.00

Manufacturing Expenses

245.91

255.92

249.39

305.59

328.59

334.70

315.54

Selling and Distribution Expenses

2,094.50

1,884.85

1,898.34

1,706.33

1,755.17

1,661.56

1,713.52

Other Expenses

-21.49

-22.84

-21.64

-25.78

-29.80

-31.82

-27.74

Total Expenditure (Excl Depreciation)

37,217.82

38,112.16

41,030.81

37,486.40

35,280.70

35,335.09

39,460.48

Operating Profit (PBDIT) excl Other Income

1002.6

977.9000000000001

985.4000000000001

894.3000000000001

977.5

1363.6000000000001

906

Other Income

6.52

75.18

640.78

877.45

75.88

72.49

64.65

Operating Profit (PBDIT)

914.95

1,141.49

1,724.46

1,859.28

1,163.38

1,536.15

1,179.33

Interest

245.91

255.92

249.39

305.59

328.59

334.70

315.54

Exceptional Items

3.84

53.14

-1.91

-4.33

0.97

-15.39

-2.70

Gross Profit (PBDT)

3,128.05

2,890.20

2,916.66

2,648.43

2,763.22

3,041.69

2,657.65

Depreciation

0.00

239.45

234.52

218.73

Profit Before Tax

672.88

699.26

1,233.70

1,314.83

601.23

967.33

642.37

Tax

148.37

211.75

261.49

336.95

108.89

285.54

119.65

Provisions and contingencies

0.00

Profit After Tax

529.89

475.70

969.86

811.20

488.55

669.96

537.68

Extraordinary Items

0.00

Prior Period Expenses

0.00

Other Adjustments

0.00

Net Profit

529.89

475.70

969.86

811.20

488.55

669.96

537.68

Share in Profit of Associates

0.00

Minority Interest

28.54

29.19

44.03

204.21

31.94

38.41

4.49

Other related items

0.00

Consolidated Net Profit

558.43

504.90

1,013.88

1,015.41

520.49

708.37

542.17

Equity Capital

0.00

Face Value

1.0

Reserves

26,477.26

25,998.54

26,457.79

25,471.29

24,656.92

24,338.08

24,557.70

Earnings per share (EPS)

0.11

0.1

0.19

0.16

0.1

0.13

0.11

Diluted Earnings per share

0.11

0.1

0.19

0.16

0.1

0.13

0.11

Operating Profit Margin (Excl OI)

2.38%

2.12%

2.01%

1.95%

2.35%

3.39%

2.22%

Gross Profit Margin

1.76%

2.4%

3.51%

4.04%

2.31%

3.23%

2.13%

PAT Margin

1.39%

1.22%

2.31%

2.11%

1.35%

1.83%

1.33%

Public Share Holdings (%)

0.0%

Pledged Promotor Holding (%)

0.0%

Quarterly Analysis Highlights - QoQ

Net Sales

QoQ Growth in quarter ended Sep 2025 is -2.22% vs -6.96% in Jun 2025

Consolidate Net Profit

QoQ Growth in quarter ended Sep 2025 is 10.60% vs -50.20% in Jun 2025

Operating Profit (PBDIT) excl Other Income

QoQ Growth in quarter ended Sep 2025 is -14.81% vs -1.61% in Jun 2025

Interest

QoQ Growth in quarter ended Sep 2025 is -3.91% vs 2.61% in Jun 2025

Operating Profit Margin (Excl OI)

QoQ Growth in quarter ended Sep 2025 has improved from Jun 2025

Compare Quarterly Results Of Jointown Pharmaceutical Group Co., Ltd. With

Select Peers

Figures in Million

Consolidate Quarterly Results

Change(CNY)

Change(%)

Net Sales

38,220.37

Other Operating Income

0.00

Total Operating income

38,220.37

Raw Material Cost

35,092.31

Purchase of Finished goods

0.00

(Increase) / Decrease In Stocks

0.00

Employee Cost

0.00

Power Cost

0.00

Manufacturing Expenses

245.91

Selling and Distribution Expenses

2,094.50

Other Expenses

-21.49

0.00

-21.49

Total Expenditure (Excl Depreciation)

37,217.82

Operating Profit (PBDIT) excl Other Income

1,002.55

0.00

1,002.55

Other Income

6.52

Operating Profit (PBDIT)

914.95

Interest

245.91

Exceptional Items

3.84

Gross Profit (PBDT)

3,128.05

Depreciation

0.00

Profit Before Tax

672.88

Tax

148.37

Provisions and contingencies

0.00

Profit After Tax

529.89

Extraordinary Items

0.00

Prior Period Expenses

0.00

Other Adjustments

0.00

Net Profit

529.89

Share in Profit of Associates

0.00

Minority Interest

28.54

Other related items

0.00

Consolidated Net Profit

558.43

Equity Capital

0.00

Face Value

1.00

0.00

Reserves

26,477.26

Earnings per share (EPS)

0.11

Diluted Earnings per share

0.11

Operating Profit Margin (Excl OI)

2.38%

0.00

2.38%

Gross Profit Margin

1.76%

0.00

1.76%

PAT Margin

1.39%

0.00

1.39%

Public Share Holdings (%)

0.00

0.00%

Pledged Promotor Holding (%)

0.00

0.00%

Quarterly - Net Sales

Net Sales 3,822.04 Million

in Sep 2025

Figures in Million

QoQ Growth in quarter ended Sep 2025 is -2.22% vs -6.96% in Jun 2025

YoY Growth in quarter ended Sep 2025 is 5.41% vs 3.57% in Sep 2024

Quarterly - Consolidate Net Profit

Consolidate Net Profit 55.84 Million

in Sep 2025

Figures in Million

QoQ Growth in quarter ended Sep 2025 is 10.60% vs -50.20% in Jun 2025

YoY Growth in quarter ended Sep 2025 is 7.28% vs 12.54% in Sep 2024

Quarterly - Operating Profit (PBDIT)

Operating Profit (PBDIT) 90.84 Million

in Sep 2025

Figures in Million

QoQ Growth in quarter ended Sep 2025 is -14.81% vs -1.61% in Jun 2025

YoY Growth in quarter ended Sep 2025 is -16.47% vs 9.19% in Sep 2024

Quarterly - Interest

Interest 24.59 Million

in Sep 2025

Figures in Million

QoQ Growth in quarter ended Sep 2025 is -3.91% vs 2.61% in Jun 2025

YoY Growth in quarter ended Sep 2025 is -25.17% vs -6.94% in Sep 2024

Quarterly - Operating Profit Margin (Excl OI)

Operating Profit Margin (Excl OI) 2.38%

in Sep 2025

Figures in %

QoQ Growth in quarter ended Sep 2025 has improved from Jun 2025

YoY Growth in quarter ended Sep 2025 has improved from Sep 2024